"N-Methyl-3,4-methylenedioxyamphetamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
Below are MeSH descriptors whose meaning is more general than "N-Methyl-3,4-methylenedioxyamphetamine".
Below are MeSH descriptors whose meaning is more specific than "N-Methyl-3,4-methylenedioxyamphetamine".
This graph shows the total number of publications written about "N-Methyl-3,4-methylenedioxyamphetamine" by people in this website by year, and whether "N-Methyl-3,4-methylenedioxyamphetamine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "N-Methyl-3,4-methylenedioxyamphetamine" by people in Profiles.
Brewerton TD, Wang JB, Lafrance A, Pamplin C, Mithoefer M, Yazar-Klosinki B, Emerson A, Doblin R. MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J Psychiatr Res. 2022 05; 149:128-135.
Brewerton TD, Lafrance A, Mithoefer MC. The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD. Med Hypotheses. 2021 Jan; 146:110367.
Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018 06; 5(6):486-497.
Wagner MT, Mithoefer MC, Mithoefer AT, MacAulay RK, Jerome L, Yazar-Klosinski B, Doblin R. Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol. 2017 08; 31(8):967-974.
Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016 May; 3(5):481-8.
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, Michel Y, Brewerton TD, Doblin R. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol. 2013 Jan; 27(1):28-39.
Albaugh DL, Rinker JA, Baumann MH, Sink JR, Riley AL. Rats preexposed to MDMA display attenuated responses to its aversive effects in the absence of persistent monoamine depletions. Psychopharmacology (Berl). 2011 Aug; 216(3):441-9.
Buchanan HA, Daéid NN, Kerr WJ, Carter JF, Hill JC. Role of five synthetic reaction conditions on the stable isotopic composition of 3,4-methylenedioxymethamphetamine. Anal Chem. 2010 Jul 01; 82(13):5484-9.
Verduin ML, Payne RA, McRae AL, Back SE, Simpson SA, Sarang RY, Brady KT. Assessment of club drug use in a treatment-seeking sample of individuals with marijuana dependence. Am J Addict. 2007 Nov-Dec; 16(6):484-7.
Budisavljevic MN, Stewart L, Sahn SA, Ploth DW. Hyponatremia associated with 3,4-methylenedioxymethylamphetamine ("Ecstasy") abuse. Am J Med Sci. 2003 Aug; 326(2):89-93.